September 19, 2016 5:26pm

… It doesn't help volume that we're lacking any noteworthy news

Pre-open indication’s tally:  6 hits <CLBS, CYTX, HSGX, KOOL, ONCE and STML> and 1 miss <CAPR>

 

I answer one question; in which company should investors put, keep and commit their money!

 

Do you care what happened today, you should because it has implications to Tuesday's sector activity?  

Subscribe or lose a portfolio advantage!

 

 

I say what others won't, so you can do what others can't!

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

 

U.S. equities closed mostly flat on Monday after a choppy session, as investors geared up for two key central bank meetings.

The NASDAQ closed DOWN -9.54 or -0.18% to 5,235.03 and the DOW closed DOWN -3.63 or -0.02% to 18,120.17.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was positive with an A/DL of 27/15 and 1 flat;
  • The mid-day was neutral with an A/DL of 20/20 and 3 flats;
  • The closing bell dipped negative with A/DL of 16/22 and 5 flats;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCGT&RT) sector was positive at the opening bell, dipped neutral at the mid-day with the sector closing negative.

I keep telling investors in the a.m. to check the indexes:  

  • The iShares Russell 2000 (IWM) indicated a positive +0.43% and was UP +0.66% while the iShares Nasdaq Biotechnology (IBB) did NOT indicated this a.m. and closed DOWN -0.04% at the close.

Sector stocks bounced around as investors <should> brace for more downside as the quarter draws to an end.

  • Trading is driving the sector’s bus and there are less than nothing catalysts and milestones to be realized by the end of Q3.

Thus, what expectations have we as investors to look forward to?

  • Volume is still low, volatility floats with momentum and that’s low … which also says … to me – caution about the next few weeks.

The start of the week does provide us with any insight, since we know to expect the unexpected.

  • However, I did state Monday would be a down day based on the “pattern” of the advance/decline lines (A/DL) and negative versus positive closings over the past eleven sessions.

I maintain we will see the usual pull/push pricing as most equities will remain sideways as the week ends!

 

Call me cantankerous, contrarian or even a curmudgeon but at the least I get it right and investors make money!

 

 

Pre-open indication’s tally:  6 hit and 1 miss:

  • Capricor (CAPR) closed UP +$0.18 – miss;
  • Caladrius Biosciences (CLBS) DOWN -$0.21 – hit;
  • Cesca Therapeutics (KOOL) closed UP +$0.065 – hit;
  • Cytori Therapeutics (CYTX) closed UP +$0.07 – hit;
  • Histogenics (HSGX) closed DOWN -$0.14 – hit;
  • Spark Therapeutics (ONCE) closed DOWN -$1.76 – hit;
  • Stemline (STML) closed DOWN -$0.07 – hit;

 

               

Today’s Bottom Line:

The compass is spinning with NO sense of direction …

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Monday traded near 15.3;
  • Friday traded near 16.2;
  • Thursday traded near 15.79 – 13% lower;
  • Wednesday traded 18.14 – 1.18% lower
  • Tuesday traded at 18.74 – 24% higher;
  • Last Monday traded 15.7 – 13% lower;

 

 

Decliners:

  • Histogenics (HSGX) -4.36% after Friday’s -6.69% after Thursday’s -1.21% ;
  • Caladrius Biosciences (CLBS) -4.18%;
  • Applied Genetics Technologies (AGTC) -3.76%;
  • Kite Pharma (KITE) -2.81%;
  • Spark therapeutics (ONCE) -2.76%

 

Advancers:

  • Northwest Bio (NWBO) +23.28% after Friday’s +12.59% after Thursday’s-18.81% after Wednesday’s +8.23% after Tuesday’s +42.61% after Monday’s +17.56% or +$0.0597;
  • Asterias Biotherapeutics (NYSEMKT: AST) +12.66%;
  • Regenxbio (RGNX) +5.57%;
  • Capricor (CAPR) +5.04% after Friday’s -4.03% after Thursday’s) -1.79% after Wednesday’s +4.86%; ;
  • Neuralstem (CUR) +4.1% after Friday’s +10.65% or +$0.03 ;

 

Flat:                                                            

  • Athersys (ATYHX) at $1.97;
  • Biostage (BSTG) at $1.04;
  • BioTime (NYSEMKT: BTX) at $3.40;
  • ReNeuron (RENE.L) at $2.625;
  • Vericel (VCEL) at $2.37

                                                                                                                               

 

Volume spikes that stand out: 

  • Northwest Bio (NWBO) – 9th day <9.8 M shares after Friday’s 4.29 M shares versus Thursday’s 5.35 M shares versus Wednesday’s 7.52 M shares compared with Tuesday’s 22.346 M shares versus 3 month average = 1.3 M>;
  • ReNeuron (RENE.L) 3.295 M shares;
  • Neuralstem (CUR) 2.184 M shares ;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.